[Market Focus] Samyang Biopharm Hits Upper Price Limit on First Trading Day
Samyang Biopharm, the pharmaceutical and biotechnology subsidiary of Samyang Group, hit the upper price limit on its first day of trading on the Korea Exchange following a spin-off.
As of 10:50 a.m. on November 24, Samyang Biopharm was trading at 30,200 won, up 29.89% from its opening price.
This listing was carried out through a direct listing method after being spun off from Samyang Holdings, the holding company of Samyang Group. The total number of listed shares is 7,435,870.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
As an independent corporation specializing in pharmaceutical and biotechnology businesses, Samyang Biopharm plans to strengthen its global competitiveness by focusing on high-performance bio products such as biodegradable surgical sutures, gene delivery systems, and anticancer drugs.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.